Trametinib and Akt Inhibitor GSK2141795 in Treating Patients With Acute Myeloid Leukemia
Status:
Terminated
Trial end date:
2016-01-01
Target enrollment:
Participant gender:
Summary
This phase II trial studies how well trametinib and protein kinase B (Akt) inhibitor
GSK2141795 work in treating patients with acute myeloid leukemia. Trametinib and Akt
inhibitor GSK2141795 may stop the growth of cancer cells by blocking some of the enzymes
needed for cell growth.